| Bioactivity | TZD18 is a potent and orally active PPARα and PPARγ dual agonist with IC50 values of 0.028, 0.057, >10 µM for PPARα, PPARγ, PPARδ, respectively. TZD18 reduces plasma levels of both glucose and triglycerides in diabetic mice. TZD18 has the potential for the research of type 2 diabetes[1]. |
| In Vivo | TZD18 (3, 10 mg/kg; p.o.; daily for 11 days) 可完全纠正糖尿病小鼠血浆中升高的葡萄糖和甘油三酯水平[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: |
| CAS | 228577-00-2 |
| Formula | C27H27NO5S |
| Molar Mass | 477.57 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Guo Q, et al. A novel peroxisome proliferator-activated receptor alpha/gamma dual agonist demonstrates favorable effects on lipid homeostasis. Endocrinology. 2004 Apr;145(4):1640-8. |